New MedWatch changes will overload industry, FDA told
This article was originally published in Clinica
US industry association AdvaMed is urging the FDA to reconsider a proposal to revamp its adverse event reporting form. It would be the second overhaul in two years.
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.